
IDEAS ITN
491 posts

IDEAS ITN
@IDEAS_ITN
IDEAS is a European training network for early stage researchers working on statistical methods for early drug development.













In #Vienna today? Join #IDEAS and the International Biometric Society @IBSstats for our joint seminar at the Medical University of Vienna @MedUni_Wien from 12.30 this afternoon! The full agenda and abstracts can be found below: ideas-itn.eu/wp-content/upl… #MSCA #H2020 #statistics

In #Vienna today? Join #IDEAS and the International Biometric Society @IBSstats for our joint seminar at the Medical University of Vienna @MedUni_Wien from 12.30 this afternoon! The full agenda and abstracts can be found below: ideas-itn.eu/wp-content/upl… #MSCA #H2020 #statistics



Join IDEAS at our joint seminar with IBS on 29/11/208 at the Medical University of Vienna @MedUni_Wien Full programme and abstracts can be found here: ideas-itn.eu/wp-content/upl… … More details available on our website at: ideas-itn.eu/join-the-ideas… #MSCA #H2020 #TravelTuesday

Join IDEAS at our joint seminar with IBS on 29/11/208 at the Medical University of Vienna @MedUni_Wien Full programme and abstracts can be found here: ideas-itn.eu/wp-content/upl… … More details available on our website at: ideas-itn.eu/join-the-ideas… #MSCA #H2020 #TravelTuesday

Check out the new publication by our ESR Nicolas Ballarini @nicoballarini on "Subgroup identification in clinical trials via the predicted individual treatment effect" in PLOS ONE! journals.plos.org/plosone/articl… #ResearchImpactEU #H2020 #MSCA #congratulations

Check out the new publication by our ESR Nicolas Ballarini @nicoballarini on "Subgroup identification in clinical trials via the predicted individual treatment effect" in PLOS ONE! journals.plos.org/plosone/articl… #ResearchImpactEU #H2020 #MSCA #congratulations



Yesterday enjoying great talks by @pmozgunov and @thomas_jaki at the Early Phase Adaptive Trials Workshop! So delighted about our reunion in LA as well! @IDEAS_ITN

Our recent work with @thomas_jaki and Xavier Paoletti on a randomised dose-escalation design for dual-agent oncology trials with an immunotherapy is now available in Open Access. Interested in questions beyond MTD selection in Phase I? Check it out! tandfonline.com/doi/full/10.10…






